U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07135219) titled 'A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy' on Aug. 01.
Brief Summary: The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.
Study Start Date: July 16
Study Type: INTERVENTIONAL
Condition:
Immunoglobulin A Nephropathy (IgAN)
Intervention:
DRUG: Biological: cizutamig
Cizutamig will be dosed according to the protocol.
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Peking University First Hospital
Published by HT Digital Content Services with permission from Health Daily Digest....